| Line 12: | Line 12: | ||
===2021 | ===2021: [https://www.clivebates.com/documents/NLFlavoursResponseJan2021.pdf Regulation of e-cigarette flavours – a response]=== | ||
*Testimony in Netherlands pertaining to a potential flavour / flavor ban. This document responds to the proposed Decree of the State Secretary for Health, Welfare and Sport on the regulation of e-cigarette flavours in the Netherlands. | |||
*Signed by 24 experts from around the world | *Signed by 24 experts from around the world | ||
*Covers 12 key points including | *Covers 12 key points | ||
**Sets conflicting objectives and takes a “war on drugs” approach to nicotine. | |||
**Adopts false and misleading claims about the risks of e-cigarettes. | |||
**Draws on irrelevant information about an outbreak of lung injuries in North America. | |||
**Misunderstands “dual-use”. | |||
**Asserts a “gateway effect” but there is more likely to be a diversion away from smoking. | |||
**Takes a simplistic approach to youth risk behaviours and fails to demonstrate benefits to adolescent public health. | |||
**Ignores perverse consequences of prohibition, even though these are foreseeable. | |||
**Fails to show benefits for adolescents or address concerns it may cause harm to young people. | |||
**Ignores the harmful effects of a vaping flavour ban on adults. | |||
**Creates regulatory protection for the cigarette trade. | |||
**Violates important regulatory principles, including those underpinning the European Union internal market. | |||
**Proposes an illiberal policy and fails to recognise a major global public health opportunity. | |||
*Acknowledgement: We confirm that signatories report no conflicts with respect to FCTC Article 5.3 and no financial conflicts of interest with respect to tobacco or e-cigarette companies under the International Committee of Medical Journal Editors (ICJME) reporting standard. | |||
edits